Detalhe da pesquisa
1.
RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature.
Blood
; 132(20): 2154-2165, 2018 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30181174
2.
Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma.
Ann Hematol
; 98(9): 2139-2150, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-31240472
3.
Advanced Imaging Modalities to Monitor for Cardiotoxicity.
Curr Treat Options Oncol
; 20(9): 73, 2019 08 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31396720
4.
Durable graft-versus-leukaemia effects without donor lymphocyte infusions - results of a phase II study of sequential T-replete allogeneic transplantation for high-risk acute myeloid leukaemia and myelodysplasia.
Br J Haematol
; 180(3): 346-355, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29076145
5.
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
N Engl J Med
; 373(7): 621-31, 2015 Aug 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-26035255
6.
Cessation of Ciprofloxacin Prophylaxis in Hemato-Oncology Patients.
Clin Infect Dis
; 75(1): 178-179, 2022 08 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34864924
7.
Reduced intensity allogeneic hematopoietic stem cell transplantation is a safe and effective treatment option in high-risk myeloma patients - a single centre experience.
Br J Haematol
; 193(2): 420-423, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33713421
8.
Acute myeloid leukemia does not deplete normal hematopoietic stem cells but induces cytopenias by impeding their differentiation.
Proc Natl Acad Sci U S A
; 110(33): 13576-81, 2013 Aug 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-23901108
9.
Clinical outcome of coronavirus disease 2019 in haemato-oncology patients.
Br J Haematol
; 190(2): e64-e67, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32420609
10.
Extended follow-up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi-centre phase I/II Clinical Trial).
Br J Haematol
; 185(3): 573-578, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30125960
11.
Clinical proof of concept for a safe and effective NF-κB-targeting strategy in multiple myeloma.
Br J Haematol
; 185(3): 588-592, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30255568
12.
Long-term survival with low toxicity after allogeneic transplantation for acute myeloid leukaemia and myelodysplasia using non-myeloablative conditioning without T cell depletion.
Br J Haematol
; 162(4): 525-9, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23718277
13.
Differential and tumor-specific expression of CD160 in B-cell malignancies.
Blood
; 118(8): 2174-83, 2011 Aug 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-21715317
14.
T-cell replete fludarabine/cyclophosphamide reduced intensity allogeneic stem cell transplantation for lymphoid malignancies.
Br J Haematol
; 157(5): 580-5, 2012 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-22449197
15.
Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction.
Blood
; 115(10): 1976-84, 2010 Mar 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-20053758
16.
Optimising cardiovascular care of patients with multiple myeloma.
Heart
; 107(22): 1774-1782, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33820757
17.
How to Simplify the Evaluation of Newly Introduced Chemotherapeutic Interventions in Myeloma.
Clin Hematol Int
; 3(1): 27-33, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-34595464
18.
Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells.
Blood
; 112(3): 568-75, 2008 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18523148
19.
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study.
Blood Cancer J
; 10(9): 91, 2020 09 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32887873
20.
Patterns of recruitment into acute myeloid leukaemia (AML) 15 and outcome for young patients with AML at a single referral centre.
Br J Haematol
; 145(1): 40-4, 2009 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-19210510